<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02880280</url>
  </required_header>
  <id_info>
    <org_study_id>BeijingChildrens-01</org_study_id>
    <nct_id>NCT02880280</nct_id>
  </id_info>
  <brief_title>Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin Treat Congenital Hypogonadotropic Hypogonadism</brief_title>
  <official_title>Human Menopausal Gonadotropin Combining With Human Chorionic Gonadotropin is Superior to Human Chorionic Gonadotropin in Therapeutic Efficacy in Adolescent Boys With Congenital Hypogonadotropic Hypogonadism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Children's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observe the therapeutic efficacy of human menopausal gonadotropin combining with human
      chorionic gonadotropin in adolescent boys with congenital hypogonadotropic hypogonadism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Observe safety and efficacy of human menopausal gonadotropin and human chorionic gonadotropin
      treating congenital hypogonadotropic hypogonadism in teenagers; which as clinic
      recommendation, may provide clinical basis for establishing standard treatment guideline in
      the future. Establish technological process and follow-up precept for human menopausal
      gonadotropin and human chorionic gonadotropin injection treating congenital hypogonadotropic
      hypogonadism in teenagers. And find safety and effective dose for teenagers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>testicular volume</measure>
    <time_frame>Change from Baseline testicular volume at 3 months after treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The levels of testosterone serum (It were measured with chemiluminescent immunoassay Elecsys)</measure>
    <time_frame>Testosterone changes from 3 months onwards after treatment compared to pretreatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Kallmann Syndrome</condition>
  <condition>Hypogonadotropic Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Human Menopausal Gonadotropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human menopausal gonadotropin contains follicle-stimulating hormone (FSH) and luteinizing hormone (LH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Human Chorionic Gonadotropin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human chorionic gonadotropin (hCG) is a hormone produced by the embryo after implantation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Menopausal Gonadotropin</intervention_name>
    <description>Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers</description>
    <arm_group_label>Human Menopausal Gonadotropin</arm_group_label>
    <other_name>Human Menopausal Gonadotropin(hMG)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Chorionic Gonadotropin</intervention_name>
    <description>Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers</description>
    <arm_group_label>Human Menopausal Gonadotropin</arm_group_label>
    <arm_group_label>Human Chorionic Gonadotropin</arm_group_label>
    <other_name>Human Chorionic Gonadotropin(hCG)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Criteria A

          -  Boy &gt;14yr without any sign of puberty, testis &lt;4ml

          -  BA ≥12yr

          -  Sex hormone (LH,FSH, T) are pre-pubertal level

          -  No other hormones problems (other pituitary glands axis are normal except gonad axis)

          -  No space occupying lesion, No tumor on MRI of pituitary and hypothalamus area

          -  Kallmann's syndrome(KS) patients may companies with dysosmia or dysplasia of olfactory
             bulb or olfactory tract on MRI

          -  Karyotype is 46，XY

          -  Exclude chronic diseases, malnutrition

        Criteria B

          -  For the boy &lt;14yr. who companies with micropenis or cryptorchid or hypospadias and
             they have anosmia or dysplasia of olfactory bulb/olfactory sulcus/olfactory structs on
             MRI include in.

        Criteria C

          -  As the phenotype of hypogonadotropic hypogonadism are variant, some of them may have
             partial puberty. So, we enrolled them when they have testis volume &gt;4ml or the
             testosterone level 〉200ng/L，companies anosmia or dysplasia of olfactory bulb
             /olfactory sulcus/ olfactory structs on MRI, and the puberty arrested in half a year.
             These patients can be diagnosed as Kallmann Syndrome.

        Exclusion Criteria:

          -  Any ascertain reason contributes to the non puberty development (Chromosome abnormal,
             trauma, surgeries) or any ascertain disease such as Prader-Willi syndrome or
             hypergonadotropic hypogonadism

          -  Systemic diseases (such as chronic kidney failure, Mediterranean anemia, poor
             controlled diabetes)

          -  Protein-energy malnutrition

          -  Eating disorder (such as anorexia nervosa, binge eating)

          -  Any brain diseases history: tumors in brain or pituitary or after their surgeries
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>138 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunxiu Gong, doctor</last_name>
    <role>Study Director</role>
    <affiliation>Beijing Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Liu, master</last_name>
    <phone>+8615001091953</phone>
    <email>judyjudy5479@aliyun.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chunxiu Gong, doctor</last_name>
    <phone>+8613370115001</phone>
    <email>chunxiugong@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Children's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100045</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Liu, master</last_name>
      <phone>+8615001091953</phone>
      <email>judyjudy5479@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Chunxiu Gong, doctor</last_name>
      <phone>+8613370115001</phone>
      <email>chunxiugong@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2016</study_first_posted>
  <last_update_submitted>August 25, 2016</last_update_submitted>
  <last_update_submitted_qc>August 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Children's Hospital</investigator_affiliation>
    <investigator_full_name>Chunxiu Gong</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
    <mesh_term>Kallmann Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Menotropins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

